Skip Navigation
Skip to contents

J Korean Acad Nurs : Journal of Korean Academy of Nursing

OPEN ACCESS

Articles

Page Path
HOME > J Korean Acad Nurs > Volume 45(1); 2015 > Article
Original Article
Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer
Jin-Hee Park, Sun Hyoung Bae, Yong-Sik Jung, Young-Mi Jung
Journal of Korean Academy of Nursing 2015;45(1):118-128.
DOI: https://doi.org/10.4040/jkan.2015.45.1.118
Published online: February 27, 2015

1College of Nursing, Ajou University, Suwon, Korea.

2Department of Nursing, College of Medicine, Dong-A University, Busan, Korea.

3Department of Surgery, School of Medicine, Ajou University, Suwon, Korea.

Address reprint requests to: Bae, Sun Hyoung. Department of Nursing, College of Medicine, Dong-A University, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea. Tel: +82-51-240-2877, Fax: +82-51-240-2920, shyoung@dau.ac.kr
• Received: September 12, 2014   • Revised: October 7, 2014   • Accepted: January 13, 2015

© 2015 Korean Society of Nursing Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution NoDerivs License. (http://creativecommons.org/licenses/by-nd/4.0/) If the original work is properly cited and retained without any modification or reproduction, it can be used and re-distributed in any format and medium.

  • 214 Views
  • 2 Download
  • 21 Crossref
  • 17 Scopus
prev next
  • Purpose
    Evidence suggests that some patients with breast cancer experience cognitive difficulties following chemotherapy. This longitudinal study was done to examine the prevalence of cognitive impairment and trajectory of cognitive function over time in women with breast cancer, who received adjuvant chemotherapy.
  • Methods
    Participants were 137 patients with breast cancer. They completed neuropsychological tests and the Functional Assessment of Cancer Therapy-Cognitive Function before adjuvant therapy (pretest), toward the end of adjuvant therapy (posttest), and 6 months after the completion of adjuvant therapy (follow-up test). Of the patients, 91 were treated with adjuvant chemotherapy and 46 patients who did not receive chemotherapy made up the comparison group. A reliable-change index and repeated-measure ANOVA were used for statistical analyses.
  • Results
    At the posttest point, over 30% of patients showed complex cognitive impairment and reported greater difficulty in subjective cognitive function. At the follow-up test point, 22.0% of patients exhibited complex cognitive impairment and 30.8% of patients complained of subjective cognitive impairment. Repeated-measure ANOVA showed significant decreases after receiving chemotherapy followed by small improvements 6 months after the completion of chemotherapy in cognitive domains of change for attention and concentration, memory, executive function, and subjective cognitive function.
  • Conclusion
    These results suggest that chemotherapy in patients with breast cancer may be associated with objective and subjective cognitive impairments. Further studies are needed to explore the potential risk factors and predictor of chemotherapy-related cognitive changes. Also nursing interventions for prevention and intervention of cognitive impairments should be developed and tested.
  • 1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46(2):109–123. ArticlePubMedPMC
  • 2. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. J Clin Nurs. 2010;19(9-10):1362–1370. ArticlePubMed
  • 3. Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12(4):279–287.ArticlePubMed
  • 4. Park JH, Bae SH. A meta-analysis of chemotherapy related cognitive impairment in patients with breast cancer. J Korean Acad Nurs. 2012;42(5):644–658. ArticlePubMed
  • 5. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3:Suppl 3. S84–S90.ArticlePubMed
  • 6. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treat Rev. 2012;38(7):926–934. ArticlePubMed
  • 7. Myers JS. Chemotherapy-related cognitive impairment: The breast cancer experience. Oncol Nurs Forum. 2012;39(1):E31–E40. ArticlePubMed
  • 8. Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: Considerations in selection of a control group. J Clin Exp Neuropsychol. 2013;35(4):435–444. ArticlePubMed
  • 9. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647–1656. ArticlePubMedPDF
  • 10. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: A controlled comparison. Cancer. 2009;115(8):1776–1783. ArticlePubMed
  • 11. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–1913. ArticlePubMed
  • 12. Ouimet LA, Stewart A, Collins B, Schindler D, Bielajew C. Measuring neuropsychological change following breast cancer treatment: An analysis of statistical models. J Clin Exp Neuropsychol. 2009;31(1):73–89. ArticlePubMed
  • 13. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15(6):951–962. ArticlePubMed
  • 14. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–2299. ArticlePubMed
  • 15. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–113. ArticlePubMedPMC
  • 16. Avisar A, River Y, Schiff E, Bar-Sela G, Steiner M, Ben-Arye E. Chemotherapy-related cognitive impairment: Does integrating complementary medicine have something to add? Review of the literature. Breast Cancer Res Treat. 2012;136(1):1–7. ArticlePubMedPDF
  • 17. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–3870. ArticlePubMed
  • 18. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20(1):76–89. ArticlePubMed
  • 19. Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007;34(5):997–1005. ArticlePubMed
  • 20. Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: A controlled longitudinal study. Breast Cancer Res Treat. 2010;123(1):25–34. ArticlePDF
  • 21. Wagner LI, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: Development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7(6):W32–W39.
  • 22. Chelune GJ, Naugle RI, Lüders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: Practice effects and base-rate information. Neuropsychology. 1993;7(1):41–52. Article
  • 23. Lezak MD, Howieson DB, Loring DW, Hannay J, Fischer JS. Neuropsychological assessment. 4th ed. New York, NY: Oxford University Press; 2004.
  • 24. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17(2):236–241. ArticlePubMed
  • 25. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20(7):1361–1375. ArticlePubMedPDF
  • 26. Moon S, Kim SH, Kim MJ. Perceived cognitive function and related factors in Korean women with breast cancer. Asian Nurs Res. 2011;5(2):141–150. Article
  • 27. Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33–50. ArticlePubMed
  • 28. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18(2):134–143. ArticlePubMed
  • 29. Myers JS, Teel C. Oncology nurses' awareness of cognitive impairment secondary to chemotherapy. Clin J Oncol Nurs. 2008;12(5):725–729. ArticlePubMed
  • 30. Chung BY, Cho EJ. Correlates influencing cognitive impairment in breast cancer patients receiving chemotherapy. Asian Oncol Nurs. 2012;12(3):221–229. ArticlePDF
Table 1

Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

jkan-45-118-i001.jpg

*Fishers exact test; Body mass index classified according to World Health Organization Western Pacific Region, International Association for the Study of Obesity, & International Obesity Task Force (2000); CTx=Chemotherapy; DCIS=Ductal carcinoma in situ; HRTx=Hormone therapy; KRW=Korean Won; M=Mean; MRM=Modified radical mastectomy; PM=Partial mastectomy; RTx=Radiotherapy; SD=Standard deviation; TM=Total mastectomy.

Table 2

Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

jkan-45-118-i002.jpg
Table 3

Changes of Cognitive Function in Chemotherapy Group (N =91)

jkan-45-118-i003.jpg

CI=Confidence interval; CogOth=Comments from others; CogPCA=Perceived cognitive abilities; CogPCI=Perceived cognitive impairments; CogQOL=Impact on quality of life; FACT-Cog=Functional assessment of cancer therapy-cognitive function; K-COWAT=Korean Controlled Oral Word Association Test; M=Mean; MD=Mean difference; SD=Standard deviation; SE=Standard error; SVLT=Seoul Verbal Learning Test; TMT=Trail making test.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Impact of nonpharmacological interventions on cognitive impairment in women with breast cancer: A systematic review and meta-analysis
      Jin-Hee Park, Su Jin Jung, Lena J. Lee, Junghyun Rhu, Sun Hyoung Bae
      Asia-Pacific Journal of Oncology Nursing.2023; 10(4): 100212.     CrossRef
    • Factors Associated with Self-reported Memory Problems of Adult Cancer Survivors Based on the Korea National Health and Nutrition Examination Survey 2019
      Sangjin Ko
      Journal of Health Informatics and Statistics.2023; 48(1): 51.     CrossRef
    • Brain network deficits in breast cancer patients after early neoadjuvant chemotherapy: A longitudinal MRI study
      Jing Yang, Yongchun Deng, Daihong Liu, Yong Tan, Meng Lin, Xiaoyu Zhou, Jing Zhang, Hong Yu, Yixin Hu, Yu Tang, Shixi Jiang, Jiuquan Zhang
      Journal of Neuroscience Research.2023; 101(7): 1138.     CrossRef
    • Frailty and its associated factors among older adults with cancer undergoing chemotherapy as outpatients: A cross-sectional study
      Misun Jeon, Hyoeun Jang, Arum Lim, Sanghee Kim
      European Journal of Oncology Nursing.2022; 60: 102192.     CrossRef
    • The Experience of Chemotherapy Related Cognitive Impairment in Patients with Cancer
      Pok Ja Oh, Ji Hyun Kim
      Asian Oncology Nursing.2022; 22(1): 1.     CrossRef
    • Distinct sleep disturbance and cognitive dysfunction profiles in oncology outpatients receiving chemotherapy
      Vivian Huang, Lynda Mackin, Kord M. Kober, Steven M. Paul, Bruce A. Cooper, Yvette P. Conley, Marilyn J. Hammer, Jon D. Levine, Christine Miaskowski
      Supportive Care in Cancer.2022; 30(11): 9243.     CrossRef
    • Measurement, outcomes and interventions of cognitive function after breast cancer treatment: A narrative review
      Miaomiao Jia, Xiaojun Zhang, Liyuan Wei, Jinnan Gao
      Asia-Pacific Journal of Clinical Oncology.2021; 17(4): 321.     CrossRef
    • Improving preoperative breast reconstruction consultations: a qualitative study on the impact of personalised audio-recordings
      Josipa Petric, Bahara Sadri, Phillipa van Essen, Nicola Ruth Dean
      BMC Women's Health.2021;[Epub]     CrossRef
    • Study on Neurologic and Cognitive Dysfunction in Breast Cancer Patients Undergoing Chemotherapy with Resting State fMRI
      Fenshan Zheng, Peiying Cao, Jie Zhou, Chunyu Li, John Norris
      World Neurosurgery.2021; 149: 388.     CrossRef
    • Changes of Cognitive Function and Fatigue following Chemotherapy in Patients with Gastrointestinal Cancer: A Prospective Controlled Study
      Pok-Ja Oh, Sun Mi Moon
      Asian Oncology Nursing.2019; 19(3): 126.     CrossRef
    • Computerized programs for cancer survivors with cognitive problems: a systematic review
      Yoonjung Kim, Sook Jung Kang
      Journal of Cancer Survivorship.2019; 13(6): 911.     CrossRef
    • Cancer treatment effects on cognition and depression: The moderating role of physical activity
      Margaret F. Bedillion, Emily B. Ansell, Gwendolyn A. Thomas
      The Breast.2019; 44: 73.     CrossRef
    • Changes of Cognitive Function and Depression following Chemotherapy in Women with Breast Cancer: A Prospective Study
      Pok Ja Oh, Jung Ran Lee, Hyun Ah Kim
      Asian Oncology Nursing.2018; 18(2): 66.     CrossRef
    • Mulheres Submetidas à Quimioterapia e suas Funções Cognitivas
      Camila Vasconcelos Carnaúba Lima, Raner Miguel Ferreira Póvoa
      Psicologia: Ciência e Profissão.2017; 37(4): 970.     CrossRef
    • Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
      Wen Li, Chen Gan, Yue Lv, Shanghu Wang, Huaidong Cheng
      Medicine.2017; 96(13): e6514.     CrossRef
    • Altered network efficiency of functional brain networks in patients with breast cancer after chemotherapy
      Han Xuan, Chen Gan, Wen Li, Zhonglian Huang, Longsheng Wang, Qianqian Jia, Zhendong Chen, Huaidong Cheng
      Oncotarget.2017; 8(62): 105648.     CrossRef
    • Chemotherapy-related Cognitive Impairment and Quality of Life in People with Colon Cancer: The Mediating Effect of Psychological Distress
      Pok Ja Oh, Jeong Hye Kim
      Journal of Korean Academy of Nursing.2016; 46(1): 19.     CrossRef
    • Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer
      Pok Ja Oh, Jung Ran Lee
      Journal of Korean Academy of Nursing.2016; 46(3): 420.     CrossRef
    • A review of traditional Korean medical treatment for cancer-related cognitive impairment
      Hye-Yoon Lee, Jung-Eun Kim, Mikyung Kim, Joo-Hee Kim
      Journal of Korean Medicine.2016; 37(3): 74.     CrossRef
    • Cognitive outcome after radiotherapy in brain tumor
      Thomas Durand, Marie-Odile Bernier, Isabelle Léger, Hervé Taillia, Georges Noël, Dimitri Psimaras, Damien Ricard
      Current Opinion in Oncology.2015; 27(6): 510.     CrossRef
    • Changes of Symptom Distress and Quality of Life in Breast Cancer Patients Receiving Adjuvant Therapy
      Jin-Hee Park, Sun Hyoung Bae, Young-Mi Jung
      Asian Oncology Nursing.2015; 15(2): 67.     CrossRef

    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer
      J Korean Acad Nurs. 2015;45(1):118-128.   Published online February 27, 2015
      Close
    • XML DownloadXML Download
    We recommend
    Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer
    Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer

    Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

    *Fishers exact test; Body mass index classified according to World Health Organization Western Pacific Region, International Association for the Study of Obesity, & International Obesity Task Force (2000); CTx=Chemotherapy; DCIS=Ductal carcinoma in situ; HRTx=Hormone therapy; KRW=Korean Won; M=Mean; MRM=Modified radical mastectomy; PM=Partial mastectomy; RTx=Radiotherapy; SD=Standard deviation; TM=Total mastectomy.

    Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

    Changes of Cognitive Function in Chemotherapy Group (N =91)

    CI=Confidence interval; CogOth=Comments from others; CogPCA=Perceived cognitive abilities; CogPCI=Perceived cognitive impairments; CogQOL=Impact on quality of life; FACT-Cog=Functional assessment of cancer therapy-cognitive function; K-COWAT=Korean Controlled Oral Word Association Test; M=Mean; MD=Mean difference; SD=Standard deviation; SE=Standard error; SVLT=Seoul Verbal Learning Test; TMT=Trail making test.

    Table 1 Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

    *Fishers exact test; Body mass index classified according to World Health Organization Western Pacific Region, International Association for the Study of Obesity, & International Obesity Task Force (2000); CTx=Chemotherapy; DCIS=Ductal carcinoma in situ; HRTx=Hormone therapy; KRW=Korean Won; M=Mean; MRM=Modified radical mastectomy; PM=Partial mastectomy; RTx=Radiotherapy; SD=Standard deviation; TM=Total mastectomy.

    Table 2 Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

    Table 3 Changes of Cognitive Function in Chemotherapy Group (N =91)

    CI=Confidence interval; CogOth=Comments from others; CogPCA=Perceived cognitive abilities; CogPCI=Perceived cognitive impairments; CogQOL=Impact on quality of life; FACT-Cog=Functional assessment of cancer therapy-cognitive function; K-COWAT=Korean Controlled Oral Word Association Test; M=Mean; MD=Mean difference; SD=Standard deviation; SE=Standard error; SVLT=Seoul Verbal Learning Test; TMT=Trail making test.


    J Korean Acad Nurs : Journal of Korean Academy of Nursing
    Close layer
    TOP